Flexion Therapeutics Inc (NASDAQ:FLXN) Director Samuel D. Colella Acquires 2,000 Shares

Flexion Therapeutics Inc (NASDAQ:FLXN) Director Samuel D. Colella acquired 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were acquired at an average cost of $10.74 per share, for a total transaction of $21,480.00. Following the purchase, the director now directly owns 25,504 shares in the company, valued at approximately $273,912.96. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

FLXN opened at $11.20 on Friday. The firm has a 50-day moving average price of $10.73. Flexion Therapeutics Inc has a 1 year low of $8.76 and a 1 year high of $24.10. The company has a debt-to-equity ratio of 3.95, a quick ratio of 6.06 and a current ratio of 7.80.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.06) by $0.10. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. The firm had revenue of $16.95 million for the quarter, compared to the consensus estimate of $14.03 million. On average, analysts expect that Flexion Therapeutics Inc will post -4.05 EPS for the current fiscal year.

FLXN has been the topic of several recent research reports. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Saturday. Northland Securities reissued a “buy” rating and issued a $20.00 price target on shares of Flexion Therapeutics in a research note on Thursday, May 9th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Benchmark raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Thursday, May 9th. Finally, BidaskClub raised Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.57.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Aperio Group LLC bought a new position in shares of Flexion Therapeutics in the 2nd quarter valued at about $46,000. Cutler Group LP grew its holdings in shares of Flexion Therapeutics by 2,650.0% in the 2nd quarter. Cutler Group LP now owns 5,500 shares of the specialty pharmaceutical company’s stock valued at $67,000 after acquiring an additional 5,300 shares in the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 6,980 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 3,490 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY bought a new position in shares of Flexion Therapeutics in the 2nd quarter valued at about $123,000. Institutional investors own 89.05% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Featured Story: Why is the price-sales ratio important?

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.